- $1.33bn
- $1.58bn
- $674.98m
- 97
- 64
- 38
- 74
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 9.61 | ||
PEG Ratio (f) | 0.19 | ||
EPS Growth (f) | 99.9% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.53 | ||
Price to Tang. Book | 5.96 | ||
Price to Free Cashflow | 9.56 | ||
Price to Sales | 1.98 | ||
EV to EBITDA | 10.78 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 4.79% | ||
Return on Equity | 5.1% | ||
Operating Margin | 10.48% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 421.03 | 429.65 | 541.53 | 666.82 | 674.98 | 692.32 | 760.64 | 14.88% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +872.11 | +2724.11 | -55.77 | -69.5 | +123.24 | +154.91 | +26.56 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Directors
- David Stack CHM (69)
- Charles Reinhart CFO (60)
- Max Reinhardt CEX (50)
- Kristen Williams CAD (47)
- Charles Laranjeira OTH (55)
- Dennis McLoughlin OTH (55)
- Roy Winston OTH (60)
- Paul Hastings LED (61)
- Christopher Christie DRC (58)
- Laura Brege IND (63)
- Mark Froimson IND (60)
- Yvonne Greenstreet IND (58)
- Mark Kronenfeld IND (66)
- John Longenecker IND (73)
- Gary Pace IND (73)
- Andreas Wicki IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 22nd, 2006
- Public Since
- February 3rd, 2011
- No. of Shareholders
- 11
- No. of Employees
- 711
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 46,500,778
- Address
- 5401 West Kennedy Boulevard, Suite 890, TAMPA, 33609
- Web
- https://www.pacira.com/
- Phone
- +1 8135536680
- Contact
- Susan Mesco
- Auditors
- KPMG LLP
Upcoming Events for PCRX
Pacira Biosciences Inc Annual Shareholders Meeting
Q2 2024 Pacira Biosciences Inc Earnings Release
Similar to PCRX
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
Annexon
NASDAQ Global Select Market
FAQ
As of Today at 18:16 UTC, shares in Pacira Biosciences are trading at $28.67. This share price information is delayed by 15 minutes.
Shares in Pacira Biosciences last closed at $28.67 and the price had moved by -25.73% over the past 365 days. In terms of relative price strength the Pacira Biosciences share price has underperformed the S&P500 Index by -43.65% over the past year.
The overall consensus recommendation for Pacira Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Pacira Biosciences does not currently pay a dividend.
Pacira Biosciences does not currently pay a dividend.
Pacira Biosciences does not currently pay a dividend.
To buy shares in Pacira Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $28.67, shares in Pacira Biosciences had a market capitalisation of $1.33bn.
Here are the trading details for Pacira Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PCRX
Based on an overall assessment of its quality, value and momentum Pacira Biosciences is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pacira Biosciences is $46.40. That is 61.84% above the last closing price of $28.67.
Analysts covering Pacira Biosciences currently have a consensus Earnings Per Share (EPS) forecast of $2.81 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacira Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -28.33%.
As of the last closing price of $28.67, shares in Pacira Biosciences were trading -12.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pacira Biosciences PE ratio based on its reported earnings over the past 12 months is 9.61. The shares last closed at $28.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pacira Biosciences' management team is headed by:
- David Stack - CHM
- Charles Reinhart - CFO
- Max Reinhardt - CEX
- Kristen Williams - CAD
- Charles Laranjeira - OTH
- Dennis McLoughlin - OTH
- Roy Winston - OTH
- Paul Hastings - LED
- Christopher Christie - DRC
- Laura Brege - IND
- Mark Froimson - IND
- Yvonne Greenstreet - IND
- Mark Kronenfeld - IND
- John Longenecker - IND
- Gary Pace - IND
- Andreas Wicki - IND